Photocure ASA (PHCUF)
Photocure ASA operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Oslo, PS, NO. The stock last traded at $5.65, up 0.00% on the session, giving a market capitalisation of $150.3M. On trailing twelve-month figures it carries a trailing P/E of 22.37, a net margin of 7.1%. Its beta of 0.35 implies it has historically moved less than the broad market.
Photocure ASA is a specialized pharmaceutical enterprise focused on the development, manufacturing, commercialization, and distribution of medicinal products. Its operational footprint extends across multiple European nations, including the Nordic region, Germany, France, Austria, the United Kingdom, the Netherlands, and Italy, in addition to the United States. The company's primary offering, Hexvix/Cysview, aids in the identification and ongoing management of bladder cancer. Moreover, Photocure is actively progressing Cevira, a therapeutic agent in development targeting human papilloma virus (HPV) infections and pre-cancerous lesions of the cervix. The firm distributes its products to pharmaceutical wholesalers, pharmacies, and healthcare institutions through collaborative licensing arrangements. Founded in 1993, Photocure ASA maintains its corporate headquarters in Oslo, Norway.
Photocure ASA is most often compared with the following Healthcare names: